Search Results
Results found for "Brigitte Kieffer"
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
The right information at the right time can mean the difference between a breakthrough and a dead end
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
. 👉 While your team highlights compelling results , the FDA is already thinking differently.
- 📰 GPCR Weekly News, May 27 to June 2, 2024
dopamine D3/acetylcholine nicotinic receptor heteromer in dopaminergic neurons A new GRAB sensor reveals differences
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
high-throughput DNA sequencing with systematic mutagenesis to create and assess the impact of many different
- GPCR Buzz of the Week | Sep 23 - 29, 2024
Registrants will learn: The powerful applications of new cellular assays to determine GPCR ligand behavior in different
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
Investors see it differently. They are not asking for formal reports at the pitch stage.
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
By mastering the difference, discovery teams can anticipate resistance, tune selectivity, and design
- The Real Cost of Strategic Overload in Biotech
The difference is subtle internally. Externally, especially in biotech fundraising, it is decisive.
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
Registrants will learn: The powerful applications of new cellular assays to determine GPCR ligand behavior in different
- The Moment Biotech Founders Realize the Money Is Gone
What often goes unnoticed is that financial signals behave very differently.
- Nanobodies: New Dimensions in GPCR Signaling Research
rhodopsin receptor activation and investigate the role of specific regions in the switching between different
- Regulators of G-protein signaling: essential players in GPCR signaling
Besides the differences in their structural complexity, some members of the RGS family are selective
- Biotech Startup Failure: Why Teams Drift Off Course Without a Single Wrong Decision
biotech startups drift into failure without obvious mistakes , and why preventing that drift requires a different
- Targeting Intracellular Allosteric Sites in GPCRs
Interestingly, although having different chemical structures they exhibit strikingly similar binding
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
generate both numerical values (IC₅₀, Kᵢ) and spatial information that clarifies receptor behavior under different
- Why Fundraising Mistakes Kill Strong Biotech Startups
. 👉 The difference between companies that survive fundraising pressure and those that drift is not discipline
- Glyco-sulfo hotspots in the chemokine receptor system
For CCR5, it has been shown that N-terminal antibodies show different sulfo-sensitivities (Scurci I et
- An overview of the compartmentalized GPCR Signaling: Relevance and Implications
The cellular context is crucial for understanding the diverse signaling outcomes mediated by different
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
across the whole spectrum of signaling activity are identified: full antagonists, partial agonists with different receptor antagonist analogs have demonstrated powerful efficacies across a range of animal models spanning different
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
While they share similarities, there are notable differences in respect to neural network architecture
